معرفی
Dr. Alison Laing serves as an Affiliate within the School of Cancer Sciences at the University of Glasgow, maintaining active research in acute myeloid leukaemia (AML) as evidenced by her 2025 publication in the British Journal of Haematology. Her institutional email (Alison.Laing@glasgow.ac.uk) facilitates direct academic collaboration.
Her research centers on leukaemia microenvironment interactions, specifically investigating how paediatric bone marrow mesenchymal stem cells promote chemoresistance through soluble factors. This work intersects with targeted therapy development, particularly anti-CD33 approaches for both adult and childhood AML. Key focus areas include:
- Mechanisms of contact-independent leukaemia cell survival
- Developmental differences in bone marrow stromal support
- Translational applications of CD33-targeted immunotherapies
- Pediatric-specific resistance pathways in AML
Analysis of her publication record reveals consistent emphasis on therapy resistance mechanisms and microenvironmental contributions to leukaemogenesis, with increasing focus on paediatric applications in recent work. Her 2025 study represents significant advancement in understanding developmental aspects of chemoresistance.
As an Affiliate faculty member, Dr. Laing likely contributes to research training within Glasgow's cancer programs. While specific supervision details aren't public, her active publication record suggests engagement with graduate students and postdoctoral researchers. Her work appears integrated within the School of Cancer Sciences' broader haematological malignancy research initiatives, potentially collaborating with groups led by co-authors like Professor Karen Keeshan.
